Stakeholder Opinions: Skin and Soft Tissue Infections - The end of the reign of vancomycin

Table of Contents

EXECUTIVE SUMMARY

• Scope of the analysis
• Datamonitor insight into the skin and soft tissue infections market
• Contributing experts
• Related reports
• Upcoming related reports

EPIDEMIOLOGY AND DISEASE BACKGROUND

• Etiology and symptoms
  • Types of skin and soft tissue infections
  • Complicated and uncomplicated skin and soft tissue infections
  • Pathogens
  • Risk groups

• Epidemiological trends
  • SSTIs are a major driver for ambulatory care utilization
  • US
  • Incidence of MRSA is lower in Japan compared to the US and Europe
  • Europe

• Economic burden of skin and soft tissue infections

PRESENTATION, DIAGNOSIS AND REFERRAL OPTIONS

• Overview
• Presentation
• Diagnosis
  • Diagnosis of skin and soft tissue infections is commonly based purely on clinical impression
  • Guidelines for the diagnosis and management of skin and soft tissues infections are sparse across the seven major markets
  • Laboratory tests used in the diagnosis of skin and soft tissue infections

• Referral
  • Primary care physicians treat most skin and soft tissue infections, although a referral may be made in more severe cases
  • Reasons for hospital admission for SSTIs
  • Mild-to-moderate nosocomial skin and soft tissue infections are treated by the attending physician

• Unmet needs and future developments in the diagnosis of skin and soft tissue infections
  • Cepheid has developed a rapid molecular diagnostic test for SSTIs caused by MRSA and methicillin-susceptible S. aureus

CURRENT TREATMENT OPTIONS AND TRENDS

• Market overview
• Treatment guidelines
  • Guideline adherence for SSTIs is strong among specialists, but poor among primary care physicians

• Treatment options
  • Current skin and soft tissue infection therapies
  • Resistance issues for skin and soft tissue infections
  • Resistance issues are growing for bacterial skin and soft tissue infections caused by staphylococci and streptococci
  • Studies and key opinion leaders acknowledge that vancomycin is becoming less effective at treating SSTIs caused by MRSA
  • Emerging pathogens

• Treatment choice
  • Efficacy against pathogens is highly influential in treatment choice for skin and soft tissue infections, although safety and cost also play a role

UNMET NEEDS AND NEW DEVELOPMENTS

• Unmet needs and future developments
  • Gaining regulatory approval represents a significant challenge for pharmaceutical companies developing drugs for the treatment of skin and soft tissue infections
  • The different characteristics of therapies can all contribute to the uptake of new antibacterial drugs for SSTIs
  • Treatment satisfaction
  • Unmet needs in the treatment of skin and soft tissue infections

• Key pipeline drugs in development for skin and soft tissue infections
  • Telavancin
  • Ceftobiprole
  • Oritavancin
  • Ceftaroline
  • Iclaprim
  • Torezolid
  • Dalbavancin
  • Radezolid (RX-1741)
  • Delafloxacin (RX-331)
  • Razupenem (PZ-601)

BIBLIOGRAPHY

• Journal papers
• Websites

APPENDIX A

• Contributing experts

APPENDIX B

TABLES

• Table: Occurrence of pathogens causing skin and soft tissue infections in North America, Europe, Latin America, and Asia-Pacific region, 1999 - 2004
• Table: Occurrence of pathogens responsible for causing skin and soft tissue infections in the US and Canada, 1997 - 2000
• Table: Etiologic risk factors for skin and soft tissue infections and their associated bacterial causes
• Table: Drug susceptibilities of methicillin-susceptible Staphylococcus aureus isolated from SSTI outpatients across the US, France, Germany, Italy, and Spain, 2001
• Table: Drug susceptibilities of methicillin-resistant Staphylococcus aureus isolated from SSTI outpatients across the US, France, Germany, Italy, and Spain, 2001
• Table: Drug susceptibilities of methicillin-susceptible Staphylococcus aureus isolated from SSTI inpatients and intensive care unit patients across the US, France, Germany, Italy, and Spain, 2001
• Table: Drug susceptibilities of methicillin-resistant Staphylococcus aureus isolated from SSTI inpatients and intensive care unit patients across the US, France, Germany, Italy, and Spain, 2001
• Table: Drug susceptibilities of Streptococcus pyogenes isolated from SSTI inpatients and intensive care unit patients across the US, France, Germany, Italy, and Spain, 2001
• Table: Vancomycin susceptibility results for Staphylococcus aureus isolates across the five major EU markets, 2001 - 06
• Table: Importance of different characteristics of drugs in treatment choice in both the community and hospital settings